Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Disorders of Leukocytes01:27

Disorders of Leukocytes

Leukocyte disorders can lead to either leukopenia, characterized by an abnormally low leukocyte count, or leukocytosis, marked by a very high leukocyte number.
Leukopenia may result from bone marrow disorders, autoimmune diseases, and infectious diseases. For example, conditions such as multiple myeloma and aplastic anemia can impair the bone marrow's ability to produce adequate leukocytes. Similarly, autoimmune diseases like lupus and viral infections such as HIV can prompt the immune system...
Lymphoid Cells and Tissues01:18

Lymphoid Cells and Tissues

Lymphoid cells and tissues are integral to the immune system, which is crucial in maintaining our body's defense against harmful pathogens. They form the building blocks of lymphoid organs, which include the spleen, thymus, and lymph nodes.
Lymphoid cells consist of various types of immune system cells. These include B and T lymphocytes, which are responsible for producing antibodies and killing infected cells, respectively. Dendritic cells act as messengers between the innate and adaptive...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Diagnostic challenge of occult ER-positive breast carcinoma within bone marrow indolent B-cell lymphoma and response to CDK4/6 inhibitor: a case report.

Journal of medical case reports·2026
Same author

Pre-emptive versus empirical antifungal therapy in patients with febrile neutropenia with acute leukaemia: a GIMEMA study.

JAC-antimicrobial resistance·2026
Same author

Impact of fitness categorization according to SIE/SIES/GITMO criteria in therapy-related and AML-MRC receiving CPX-351.

Blood advances·2026
Same author

Combination of Metronomic Chemotherapy and Rituximab in Frail and Elderly Patients with Relapsed/Refractory Follicular Lymphoma and Ineligible for Lenalidomide Treatment: A Retrospective Analysis.

Cancers·2026
Same author

Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.

Blood advances·2026
Same author

Clinical Frailty Scale as a Predictor of Early Treatment Discontinuation in Elderly Patients With Chronic Lymphocytic Leukemia Treated With Zanubrutinib: A Multicenter Real-World Study.

Hematological oncology·2025

Related Experiment Video

Updated: Jun 30, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

Low absolute lymphocyte count is a poor prognostic factor in diffuse-large-B-cell-lymphoma.

Maria Christina Cox1, Italo Nofroni, Luigi Ruco

  • 1Department of Hematology, AO Sant'Andrea, La Sapienza University,Rome, Italy. mccox@libero.it

Leukemia & Lymphoma
|September 18, 2008
PubMed
Summary

Absolute lymphocytic count (ALC) at diagnosis is a strong negative prognostic factor for diffuse large B-cell lymphoma (DLBCL). A new ALC/R-IPI score combining ALC and revised-international-prognostic-index (R-IPI) significantly improves prognosis prediction in DLBCL patients.

More Related Videos

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Related Experiment Videos

Last Updated: Jun 30, 2026

Enhancing Tumor Content through Tumor Macrodissection
10:04

Enhancing Tumor Content through Tumor Macrodissection

Published on: February 12, 2022

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells
11:29

HPLC-based Assay to Monitor Extracellular Nucleotide/Nucleoside Metabolism in Human Chronic Lymphocytic Leukemia Cells

Published on: July 20, 2016

Area of Science:

  • Hematology
  • Oncology
  • Clinical Research

Background:

  • The prognostic value of absolute lymphocytic count (ALC) in non-Hodgkin lymphoma (NHL) is debated.
  • Accurate prognostic markers are crucial for managing diffuse large B-cell lymphoma (DLBCL).

Purpose of the Study:

  • To prospectively evaluate the prognostic value of ALC at diagnosis and post-treatment in DLBCL.
  • To develop and validate a novel prognostic score incorporating ALC and the revised-international-prognostic-index (R-IPI).

Main Methods:

  • Prospective assessment of 101 DLBCL patients.
  • Analysis of overall survival (OS), event-free survival (EFS), and progression-free survival (PFS) using log-rank tests.
  • Development of a trichotomous ALC/R-IPI prognostic score.

Main Results:

  • A low ALC (<0.84 x 10(9)/L) at diagnosis was a significant negative prognostic factor for OS, EFS, and PFS, independent of R-IPI.
  • ALC post-treatment showed no prognostic value.
  • The novel ALC/R-IPI score was the most powerful predictor in multivariate analysis for OS, EFS, and PFS.

Conclusions:

  • ALC at diagnosis is a robust independent prognostic marker in DLBCL.
  • The combined ALC/R-IPI score offers superior prognostic stratification compared to existing models.
  • This new score can aid in optimizing treatment strategies for DLBCL patients.